Pushing for Weight Management: Bariatric Interventions Benefits and Considerations - Jörn Schattenberg, MD video

Innovations in NAFLD Care Workshop 2022

Use of Intelligent Liver Function Testing in General Practice - John Dillon MB,BS,MD,MRCP(UK),FRCP(Edinburgh) video

Innovations in NAFLD Care Workshop 2022

Fatal Triple – Linking Obesity, Type-2 Diabetes, and NASH - Cyrielle Caussy, MD, PhD slides

Innovations in NAFLD Care Workshop 2022

Using the Power of Digital Innovation - Apps Transforming Weight Management - Marcus Ranney, MD

Innovations in NAFLD Care Workshop 2022

Clinical Care Pathways for the Risk Stratification of Patients - Emmanuel Tsochatzis, MD, MSc, FEBTM, FRCP, PhD

Innovations in NAFLD Care Workshop 2022

Innovations in NAFLD Care Workshop 2023

Innovations in NAFLD Care Workshop 2022

Management of DAA Failures | Gregory T. Everson, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Post-LT Renal Failure and HCV Rx | Peter Ferenci, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Obstacles to Treatment: Renal Disease, Ribavirin, DDIs | Michael Charlton, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

What Are the Treatment Options? | Maria Londoño, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Use of HCV+ Donor Grafts | Didier Samuel, MD, PhD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Achieving SVR in CTP C – MELD Purgatory | Christophe Duvoux, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

When to Treat HCV in a Waiting List Patient? | Stefano Fagiuoli, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

What Are the Treatment Options? | Xavier Forns, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Treatment Experienced GT3 patient with Cirrhosis | Geoffrey McCaughan, MD, PhD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Is Treatment Cost-effective? | Kosh Agarwal, MD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

Who Should We Treat? What is the “Point-of-No-Return”? | Norah Terrault, MD, MPH, FAASLD

Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016

HAV in a Tertiary Hospital: 2017 Epidemic vs 2009-2016 Period | Andrea Lombardi, MD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

Roundtable Discussion: Hepatitis A in HIV: the French, Italian, and Spanish Perspective | Luz Martin-Carbonero, MD, PhD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

Roundtable Discussion: Hepatitis A in HIV: the French, Italian, and Spanish Perspective | Massimo Puoti, MD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

NAFLD in HIV- infected patients | Juan Macías, MD, PhD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

Case on HEV | Antonio Rivero-Juarez, PhD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

Debate: TDF vs. TAF in HBV management | Douglas Dieterich, MD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018